Yongin, South Korea · Founded 2018 · Privately Held (backing)
Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress. Bilix is based in Yongin, South Korea and was founded in 2018. Its last reported valuation was $28.1 million in Dec 2025. It has raised $10 million.
These 15 firms already write checks for companies like Bilix. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.